| INTRODUCTION
Prostate cancer is the most commonly diagnosed non-cutaneous carcinoma and the second leading cause of cancer death in men of the United States. 1 The American Cancer Society estimates that in 2016 about 180 890 new cases of prostate cancer will be diagnosed, and there will be approximately 26 120 deaths from prostate cancer. 2 Typically prostate cancer screening has involved both total prostate specific antigen (PSA) and DRE testing. 3, 4 Although total PSA levels have a strong association with the risk of prostate cancer, there is no cut-off point of total PSA with both high sensitivity and high specificity in detecting prostate cancer. 5 With the commonly used cut-off points (2.0-4.0 ng/mL), total PSA typically has a high sensitivity, but low specificity in detecting prostate cancer. In addition, there is no consensus on the diagnostic performance of DRE for detecting prostate cancer, and the criteria used for an "abnormal" result of DRE vary among clinicians. 6, [10] [11] [12] Some studies showed that DRE, when combined with PSA and other measurements, could increase the likelihood of detecting prostate cancer on prostate biopsy. 7, 8 Roobol et al. 9 demonstrated that the prostate volume data provided by DRE contributed to a greater accuracy of the European Randomized study of Screening for Prostate Cancer (ERSPC) Risk Calculator. On the other hand, DRE was found in some other studies to have rather low diagnostic accuracy. [10] [11] [12] Different studies yielded a wide range of sensitivity and specificity for DRE. 13, 14 As a result of the low specificities of PSA and DRE testing, many men without aggressive prostate cancer continue to be subjected to unnecessary prostate biopsies and potential complications. Over 1 million prostate biopsies are performed in the United States annually, however, 77% are estimated to discover either low grade, indolent disease or no cancer at all. 15 In those men found to have indolent cancer on biopsy, many subsequently will undergo radical intervention out of clinical concern that the biopsy may have under-graded the prostate cancer, ie missed an area of high-grade tumour. Unfortunately, two-thirds of these men will be confirmed to have only Gleason 6 and thus subjected to over-treatment. 16 The high false positive rates and harm caused by unnecessary prostate biopsies, was a motivation for the U. 
| METHODS

| Study design
The current study uses prospectively collected data of 1012 men whose blood samples were obtained prior to a prostate biopsy. The study is a post hoc, retrospective analysis designed to evaluate the diagnostic performance of 4Kscore without DRE information (with levels of 4 kallikreins, age and prior biopsy status), and compared with the original 4Kscore model with DRE input.
| Patient population
The prospective, multi-institutional US 4Kscore validation study 
What's new
• The 4Kscore Test algorithm that excludes DRE information retains its excellent predictive, discriminatory accuracy for risk of high-grade cancer at prostate biopsy.
• The findings of this study indicate that the risk of aggressive prostate cancer can also be reliably provided to patients who do not have DRE information available.
the 4Kscore algorithm prospectively. The calibration was excellent and the study was completed with 4Kscore validation in the subsequent 1012 patients. All men had the serum total PSA measured and a DRE performed by a Board-certified urologist. Each patient had a blood sample for kallikrein measurement collected prior to prostate biopsy. A minimum of a ten-needle core Transrectal Ultrasound (TRUS) guided prostate biopsy was required for inclusion in the study. Exclusion criteria were: (i) a previous diagnosis of prostate cancer, (ii) DRE within 96 hour before phlebotomy, (iii) 5-alpha reductase inhibitor therapy in the previous 6 months, and (iv) invasive urological procedures that may be associated with a secondary PSA elevation within the previous 6 months. These exclusions were necessary to prevent any potential influence on kallikrein levels. The prostate biopsy histopathology was evaluated according to the established practice at each study site. Demographic and clinical information was collected in a standardised fashion. All patients provided written and informed consent for involvement in the study and collection of data and specimens after Institutional Review Board approval at each study site. 
| Laboratory methods
A venous phlebotomy sample for kallikrein measurement was collected in a K2-EDTA tube for each patient. The blood samples were obtained at the local clinical centre and transported to OPKO Lab in Nashville, TN, for measurements of the levels of the four kallikreins.
The kallikrein levels were blinded from the histopathology results.
Total PSA and free PSA levels were analysed using a Cobas instrument and Elecsys assays (Roche Diagnostics, Indianapolis, IN). Intact PSA and hK2 levels were measured using tests developed for the PerkinElmer AutoDELFIA ® instrument.
| Evaluation of the 4Kscore without DRE input
The 4Kscore Test provides a probability score ranging from <1% to >95% and reflects the probability that a man will have aggressive prostate cancer on prostate biopsy, defined as Gleason 7 or greater. The evaluation of the 4Kscore without DRE input required that the DRE term be reported as "missing" and set to "0" in the 4Kscore algorithm, and all other terms remained the same as in the original 4Kscore model.
| Statistical analysis
Our primary analysis was to determine whether omitting DRE information from the 4Kscore algorithm would affect the discrimination accuracy for aggressive prostate cancer diagnosis in men undergoing prostate biopsy. The primary outcome was the presence of aggressive prostate cancer (Gleason score 7 or greater) in a prostate biopsy specimen. In this analysis, patients with Gleason score 6 and lower, were classified the same as patients with negative biopsy.
Demographic and clinical differences between subgroups of patients with aggressive prostate cancers and without aggressive prostate cancers (including those without cancers and with Gleason 6 or below cancers) were compared using Kruskal-Wallis test for continuous variables and chi-squared test for categorical variables.
The discriminatory accuracy of the 4Kscore without DRE input was assessed with area under the receiver operating curve (AUC), calibration plot and decision curve analysis. 35 The AUC was compared between the original 4Kscore, the 4Kscore without DRE input and a base model with total PSA and patient age only. The two versions of 4Kscore were then compared with respect to the number of biopsies that could be avoided, and, the number of aggressive cancers whose diagnosis could be delayed if biopsy were performed above 4Kscore
threshold values of 7.5%. Lastly, the concordance between the original 4Kscore and the 4Kscore without DRE input at the cut-off point of 7.5% was evaluated with McNemar's test.
Statistical analyses were conducted using Stata 13.1 (StataCorp, College Station, TX).
| RESULTS
The demographic and clinical characteristics of the study population by cancer status are shown in Table 1 and the 4Kscore without DRE revealed a higher net benefit over the current standard of care (to biopsy all patients). The net benefit of the 4Kscore without DRE is very similar to that of the original 4Kscore.
The decision curves of the two versions of 4Kscore overlap across the majority of the entire range, except for the risk thresholds between 10% and 15% risk of aggressive cancer.
A cut-off of 7.5% was utilised for both versions of the 4Kscore. Test on cryopreserved samples collected more than 15 years earlier and could identify men at greatest risk for prostate cancer distant metastasis. The study also showed that men who had low risk 4Kscores
(<7.5%) had a very low risk for distant metastases in the long term and could therefore be safely followed at less frequent intervals. These results indicate that physicians and patients can safely decide to avoid or delay a biopsy when the 4Kscore Test risk is low. The ability to safely avoid prostate biopsies without compromising the detection of aggressive diseases can result in a significant reduction in number of unnecessary prostate biopsies and over treatment of indolent, Gleason 6 disease, thus addressing a chief concern formulated by the USPSTF
and other groups about current practice in the detection of prostate cancer.
The 4Kscore Test was designed to allow evaluation of risk whether DRE data are available or not. This study demonstrates that the 4Kscore model, without DRE information, retains its excellent discrimination and calibration for predicting the risk of aggressive prostate cancer. Therefore, the 4Kscore Test, with or without DRE information, identifies men who have high risk of aggressive cancer and those who are most likely to benefit from biopsy. To our knowledge, this is the first study with prospectively collected data prior to biopsy to demonstrate that the 4Kscore Test could accurately predict each individual's risk for aggressive prostate cancer in absence of DRE. Our results in this prospective study are consistent with earlier retrospective studies using the 4Kscore model, including multiple European cohorts in the ERSPC [22] [23] [24] [25] [26] [27] and the ProtecT cohort in the United Kingdom. 30 Most of these studies included DRE input in the model. Of those retrospective studies using 4Kscore without DRE, the findings were similar to those in the current study. 27, 30 Moreover, prior retrospective studies that compared the 4Kscore models with and without DRE yielded results similar to the current study. 22, 25, 26, 29 The current study compared the 4Kscore results computed with and without DRE information and determined that, using the recom- guidelines for prostate cancer. 36 These men quite possibly would have F I G U R E 2 ROC of the original 4Kscore, the 4Kscore without DRE and a model with PSA and patient age F I G U R E 3 Decision curve analysis comparing 4Kscore without DRE vs. 4Kscore. The line with the highest net benefit at a particular threshold probability for biopsy will result in the best clinical results.
been managed by Active Surveillance rather than by radiation therapy or surgical intervention. In a recent published nested control study including more than 5000 men, Stattin et al. 31 showed that a similar cut-off (7.5%) on 4Kscore Test run on a cryopreserved plasma sample collected more than 15 years earlier could identify men at greatest risk for prostate cancer distant metastasis. A limitation of the study is that this cohort only included patients who were suspected of prostate cancers and therefore, could not evaluate the diagnostic accuracy of the 4Kscore on apparently healthy men. This limitation is shared by virtually all studies of prostate cancer diagnosis, as it would not be ethical to perform biopsies on apparently healthy men. 
| CONCLUSION
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